Medline sells roughly half its revenue at a ~5% margin so that it can sell the other half at ~26%. Every lever on free cash flow per share is, directly or indirectly, a lever on that mix. Here is the full stack — quantified, sourced, and ranked.
Medline is the only company at scale that is both the manufacturer and the distributor of med-surg supplies — what the prospectus calls the "N of 1" position. The distribution business is not the business. It is the channel that carries the manufacturing business into the building.
That spread is the entire investment case. Every dollar of a customer's spend that migrates from a third-party product to a like-for-like Medline product moves from the left column to the right. No new customer required. No new truck. No new warehouse. Same delivery, same rep, same dock.
FCF/share = (EBITDA − cash interest − cash taxes − capex − ΔWC) ÷ shares. What makes Medline unusual right now is that most of these levers are pinned at or near their worst setting simultaneously — which is the arithmetic precondition for non-linear recovery.
The prospectus gives the curve explicitly: in acute care, “at the beginning of a Prime Vendor relationship, Medline Brand products typically represent approximately 10% of a customer's product mix but has the potential to reach approximately 60% Medline Brand over time” — and states the opportunity is greater in certain non-acute settings. It sizes the prize: SCS products with available like-for-like Medline Brand equivalents represented ~$4.0 billion of net sales to existing Prime Vendor customers at 31 Dec 2024, and full conversion would deliver ~$1.0 billion of incremental gross profit at historical margins — with the company's own caveat that 100% is not immediately achievable. Against ~$3.4B of guided FY26 EBITDA, this is the largest single lever Medline owns. S-1
Roughly $411M of cost was eaten deliberately. On ~$30B of revenue, every 100bp of price is ~$300M of near-pure EBITDA — about 9% of the guided base. The $243M of refunds already booked shows the legal reversal is live rather than theoretical. The open question is whether this was a share-buying investment or a euphemism for absent pricing power. Q2 call
This is why FY26 organic guidance went up twice while EBITDA went down: the top line is contractually visible 18–24 months out. The February 2025 VA award — 19 of 20 delivery orders, >$1B annually, serving over 90% of Veterans Integrated Service Networks plus IHS, BOP and HHS on a five-year term — is the anchor. Government contracts, once integrated, are close to unremovable. S-1 / PR
Between the fire, quality remediation and the transitory half of the EBITDA cut, there is plausibly $300–450M of cost that simply stops — before any insurance recovery. On 1.31B shares that is roughly $0.20–0.30 per share of free cash flow arriving without a single new customer or price increase. Q2 call
The IPO was a balance-sheet repair event before it was anything else. The May 2026 refinancing issued $1.25B of 5.000% notes due 2031 and $750M of 5.250% due 2033 plus a $2.75B term loan due 2033, retiring the 2028 term loan and redeeming $500M of 6.250% 2029 notes. Leverage has walked from ~4.9× pre-IPO to 2.9×. Each further billion repaid compounds. 8-K / 10-Q
The tell is Drazin's own framing: costs including "labor inefficiencies as we operate without automation" remain in the base. Medline lost an automated DC to the Tracy fire and replaced it inside a month with 1.6M sq ft of leased, unautomated space. Retrofitting that footprint is a dated, mechanical recovery. Layer on Mpower, the Azure-built customer control tower already delivering a >50% reduction in substitution-workflow effort and a 1–2% fill-rate gain across ten pilot systems — a retention and conversion asset rather than a revenue line. Q2 call
Non-acute settings — long-term care, ambulatory surgery, home health — buy a materially higher share of private label than hospitals do, because they lack sophisticated procurement functions and lean on the distributor to specify. Medline's fleet is diversified down to vans, so it can serve the whole continuum on one contract; most competitors cannot. Running underneath it, the Mills-era strategy of "inching up the clinical curve" — out of commodity and into surgery, infection prevention, wound care and continence with patented or education-differentiated product. That strategy is enforced in the field by Medline's own board-certified clinical staff, who train customer nurses on protocol and product together — an under-modelled moat that converts guidelines into standing orders. Transcript library
This is a negative lever today and the second-derivative kicker tomorrow. With the <3× leverage target already met and the business generating well over a billion of annual free cash flow, the moment capital allocation flips from debt paydown to repurchase — at a depressed multiple — it multiplies every lever above it on this list. The sponsor sell-down clearing is the gating event. 424B4
The S-1 names no competitor anywhere in the document. Its competition section describes categories only: other med-surg manufacturers, other distributors, and a third class most models ignore entirely. Taken segment by segment, the two halves of Medline face completely different competitive weather.
This is no longer a fight against three healthy rivals. Within twelve months of Medline's IPO, one of the big three was sold to private equity at a distressed price and another announced it was separating the business entirely.
Also in the channel: Henry Schein ($13.2B FY25, dental-weighted, non-acute and physician office rather than acute prime vendor); Concordance Healthcare Solutions (~$889M, private, continuum-focused); and regional players including Claflin and The Premier Group that lack national acute-care scale.
Here the competition is genuinely strong and well-capitalised — but fragmented by category, and structurally disadvantaged in one specific way.
| Competitor | Where it overlaps | Scale / note |
|---|---|---|
| Cardinal Health | Own-brand med products and Presource custom procedure trays | The only true mirror image — competes in both segments at once |
| Solventum (SOLV) | Advanced wound care, surgical drapes, IV site care | MedSurg $2.6B H1 FY26, +9.7% |
| Mölnlycke | Surgical drapes & gowns, advanced wound care | Private (Investor AB); repeatedly named a top Medline rival |
| Becton Dickinson | Syringes, needles, IV access | Scale manufacturer, no owned channel |
| ConvaTec · Coloplast · Smith+Nephew | Wound, ostomy, continence | Category specialists |
| Ansell, Top Glove, Hartalega | Gloves and protective apparel | Commodity, price-set |
| Halyard | Surgical gowns and drapes | Ex-Kimberly-Clark; now inside Platinum-owned O&M P&HS |
“We compete with other medical product manufacturers and distributors, as well as customer self-distribution models and outsourced logistics companies.”
Medline S-1, risk factors
Large integrated delivery networks that build their own consolidated service centres are the real long-term threat, because they do not compete inside the Prime Vendor contract — they abolish it. A system that self-distributes never enters the conversion curve at any price. This is the sharp end of the customer-consolidation risk: the biggest customers are precisely the ones with the scale to go it alone.
ALL FIGURES ABOVE FROM THE S-1. PRIME VENDOR RELATIONSHIPS REPRESENTED $16.0B OF FY2024 NET SALES; ~$8B OF NEW ANNUAL CONTRACT VALUE SIGNED OVER THE PAST SIX YEARS; NET SALES HAVE GROWN EVERY YEAR SINCE 1966 AT AN 18% CAGR.
Quotations from the Q1 and Q2 FY2026 earnings calls. Speakers are CEO Jim Boyle and CFO Mike Drazin.
“We don't act in times of uncertainty and chaos and crisis… It's better to absorb and take share than it is to take price.”
Jim Boyle, CEO — Q2 FY26
“We absorbed most of the roughly $500 million benefit and passed through only $89 million to customers.”
Mike Drazin, CFO — Q2 FY26
“We've been intentional for many, many years of investing in our business for growth ahead of the growth.”
Mike Drazin, CFO — Q2 FY26
“Roughly half of the incremental earnings impact from these factors is transitory, roughly half is more permanent.”
Mike Drazin, CFO — Q2 FY26
“Other costs, including lease expenses and labor inefficiencies as we operate without automation, will remain in our base.”
Mike Drazin, CFO — Q2 FY26
“We're adding it three to six months… in advance of the revenue realization.”
Jim Boyle, CEO — Q2 FY26, on cost timing
“We are not satisfied with the margin challenges we are currently facing; we are focused on addressing them.”
Jim Boyle, CEO — Q2 FY26
“Through the first half of the year, we achieved more than $650 million in total new customer signings, representing over 65% of our annual goal of $1 billion.”
Jim Boyle, CEO — Q2 FY26
“AutoStore manages 2,100 robots… increases throughput by 250%, reduces labor burden by 50%.”
Jim Boyle, CEO — Q1 FY26
“We have also modified our complaint review process, which we expect will increase medical device reporting or MDR submissions in the second half of the year.”
Jim Boyle, CEO — Q2 FY26
“The burden that we're feeling is a loss of a portion of a customer… just to a lack of our sales team understanding the needs of the customers and meeting them where they were.”
Jim Boyle, CEO — Q2 FY26, on retail softness
“We will use excess capital to reduce leverage… ultimately our goal is organic growth first.”
Jim Boyle, CEO — Q1 FY26
The levers above are contingent. These are the mechanisms by which they fail to convert.
Medline sells the bulk of its volume through group purchasing organisations on rigid multi-year fixed-price contracts. That is the real reason cost inflation could not be passed through — not merely management restraint. If price is contractually locked rather than voluntarily withheld, Lever 2 is not coiled; it is unavailable until contracts reprice. This is the single most important thing to verify on the next call.
The FDA issued a warning letter dated 25 March 2026 covering Namic angiographic rotating adaptor control syringes, subject to a Class I recall for loose connection or full disconnection from the manifold. The action covers more than 4 million syringes and more than 1 million procedure kits, following 250 complaints between June 2023 and February 2026, and cites CAPA failures. Because the affected syringes sit inside sterile custom procedure trays — the stickiest, highest-margin Medline Brand product — remediation means physically opening, reworking and resealing kits with manual labour. The FDA warned of possible seizure, injunction or civil penalties.
The Ninth Circuit held that Medline cannot compel a warehouse employee into arbitration, finding her exempt under the Federal Arbitration Act §1 interstate-commerce carve-out because she loads goods that cross state lines. In May 2026 the Supreme Court affirmed a broad reading of the same exemption. Wage-and-hour exposure across Medline's distribution workforce moves from confidential, individualised arbitration into public class and representative litigation — precisely as recall remediation increases manual warehouse hours.
The same hospital consolidation that drives Medline's share gains creates counterparties large enough to price it. A mega-system that understands the 5%-to-26% spread can demand the difference back. Conversion depends on the customer not fully modelling what conversion is worth to Medline.
Management attributed ~75% of the cut to internal factors. Boyle's own account of the retail miss points to commercial execution gaps beyond tariffs. Until gross margin visibly recovers, the market is entitled to read the growth as bought below cost. Sponsor overhang caps the multiple in the meantime.
This note draws on primary filings, earnings calls, and a local transcript library of secondary commentary. The three are not equally reliable and are not treated as such.
| Claim | Source | Confidence |
|---|---|---|
| $4.0B conversion opportunity; ~$1.0B incremental gross profit; 65/35 prime vendor mix | S-1 / 424B4 | Verified — company disclosure, with the company's own caveat that 100% conversion is not achievable |
| Segment sales & EBITDA shares (FY24 50.9/16.5 & 49.1/83.5; FY25 51.7/19.4 & 48.3/80.6) | S-1 / 424B4 | Verified |
| ~5% and ~26% segment margins | Derived | Arithmetic from disclosed shares; excludes unallocated corporate |
| Tariff figures, guidance, signings, automation, Tracy, leverage | Q1/Q2 FY26 calls & 10-Q | Verified — direct quotation or filed figure |
| VA award: 19 of 20 delivery orders, >$1B/yr, >90% of VISNs | Company PR, 10 Feb 2025 | Verified |
| FDA warning letter, Namic Class I recall, >4M syringes / >1M kits | FDA warning letter 723866, 25 Mar 2026 | Verified |
| Ninth Circuit FAA §1 ruling; SCOTUS affirmation May 2026 | Law360 / CRS | Verified as to holding |
| Conversion curve ~10% → ~60%; >98% PV retention; 1,300+ PV relationships / $16.0B; 69 DCs, 29M sq ft, 2,000+ trucks; $375B TAM; ~1/3 self-manufactured | S-1, business section | Verified — quoted or stated directly |
| Competitor segment revenues and margins (CAH $12.7B / $258M; MCK ~$11.5B; O&M P&HS $375M sale; HSIC $13.2B; SOLV MedSurg $2.6B) | Comps' own filings & releases | Verified |
| 20/60/20 revenue ramp; 85–90% spend commitment | Transcript library (secondary) | Directionally consistent with filings; specific percentages not independently confirmed |
| Clinical-curve strategy and clinical-education moat | Mills interview + Medline clinical training transcripts | First-hand but anecdotal; strategic colour, not a modelled input |